Neuraxis, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Neuraxis, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.57M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.69M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.46M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.68M | Apr 16, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.57M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.69M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.46M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $477.5K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $2.68M | Apr 16, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.01M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.32M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.16M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $410.2K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $2.39M | Apr 16, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.80M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($8.24M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($14.63M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($8.63M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($4.78M) | Apr 16, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.83M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($7.16M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($6.66M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($3.02M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($3.37M) | Apr 16, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $493.6K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $433.6K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $169.3K | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $45.0K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $225.6K | Apr 16, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.43M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($6.10M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($6.69M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($4.06M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($2.30M) | Apr 16, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.2K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $27.8K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $30.8K | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $14.7K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $1.4K | Apr 16, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.40M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.76M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $509.5K | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $1.24M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $1.48M | Apr 16, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.00M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.69M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.91M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $2.30M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $7.05M | Apr 16, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.40M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.07M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | ($1.40M) | Mar 19, 2026 |
| FY2023 | Sep 30, 2023 | ($1.06M) | Apr 16, 2024 |
| FY2024 | Dec 31, 2022 | ($5.57M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($825.7K) | Apr 16, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($64.60M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($56.80M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($48.56M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($46.97M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($33.93M) | Apr 16, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.97M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.70M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $78.6K | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $761.2K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $253.7K | Apr 16, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $228.3K | Apr 16, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 16, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 16, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.65M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 6.99M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 6.51M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 1.96M | Apr 16, 2024 |